Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1998

View Archived Issues

Seattle Genetics initiates a phase I clinical trial of SGN-10

Phase II trials of Xenova's P-gp pump inhibitor planned in U.S. and U.K.

Vanguard drops hyperphosphatemia Rx from development pipeline

MedImmune and BioTransplant initiate two new clinical studies of MEDI-507

Merck KGaA prefers alliances to mergers; signs new deal with ImClone Systems

Neoprobe to develop product for intraoperative detection of neuroblastoma

FDA grants expedited development status to Cordox as it begins phase III trials

TerraGen and Schering-Plough Research Institute establish collaborative agreement

SmithKline Beecham and Ribi announce positive HBV phase III trial data

Dendreon presents phase I/II data on APC-8020 at ASH meeting

Eisai launches new formulation of antiarrhythmic drug in Japan

SonoRx studies presented at RSNA meeting; U.S. launch imminent

AMI-227: a novel contrast agent with several potential uses in MRI

New RES-specific contrast agents enter the pipeline at Bracco

News from RSNA 98: German team describes MRI contrast agent CMD-Gd-DOTA

Elastase inhibition as a potential approach to treating acute viral myocarditis

Angiotech initiates another clinical trial with paclitaxel for treatment of psoriasis

Tularik, Knoll to collaborate on antiobesity R&D

ISS-DNA alters the immune response and prevents symptoms of allergic asthma

New antidiabetic agents from Yamanouchi have a dual mechanism of action

PLA2 inhibitors with broad potential application as antiinflammatory agents

New agents for micturition disorders discovered at Kyowa Hakko

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.